The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The humanistic and economic burden of transfusion-dependent LR-MDS
María Díez Campelo, MD, PhD, University of Salamanca, Salamanca, Spain, briefly discusses the humanistic and economic burden of transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS), highlighting the need for developing novel treatment strategies to decrease the frequency of hospital visits and improve the quality of life of patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria/Speaker: BMS, Novartis, Keros; Advisory Board: BMS, Novartis, Blueprint Medicines, GSK, Agios, Hemavan, Syros, Keros, Curis, Astex/Otsuka.
